Status:
UNKNOWN
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Peking University People's Hospital
Guangxi Medical University
Conditions:
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Stem Cell Transplantation
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic ...
Detailed Description
Philadelphia chromosome (Ph) is a reciprocal chromosomal translocation t(9;22）(q34;q11), which leads to the formation of the BCR/ABL oncogene. Ph is the most frequent cytogenetic abnormality in ALL ch...
Eligibility Criteria
Inclusion
- A patient age of 14-65 years
- Allo-HSCT recipient with ph+ ALL
- Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- patients with hematological relapse, extramedullary involvement of leukemia
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2017
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01883219
Start Date
June 1 2013
End Date
November 1 2017
Last Update
November 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515